Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cellular vaccines

J Bartholeyns1, J L Romet-Lemonne, M Chokri

  • 1IDM, Paris, France.

Research in Immunology
|December 16, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond the <i>emm</i>-type: fine-tuning Group A <i>Streptococcus</i> typing with Enn and Mrp.

Microbiology spectrum·2025
Same author

A window of opportunity for cooperativity in the T Cell Receptor.

Nature communications·2018
Same author

Soluble TLR2 and 4 concentrations in cerebrospinal fluid in HIV/SIV-related neuropathological conditions.

Journal of neurovirology·2016
Same author

Spontaneous and natural cytotoxicity receptor-mediated cytotoxicity are effector functions of distinct natural killer subsets in hepatitis C virus-infected chimpanzees.

Clinical and experimental immunology·2016
Same author

ICAM-1 and VCAM-1 are differentially expressed on blood-retinal barrier cells during experimental autoimmune uveitis.

Experimental eye research·2015
Same author

Whole blood stimulation with Toll-like receptor (TLR)-7/8 and TLR-9 agonists induces interleukin-12p40 expression in plasmacytoid dendritic cells in rhesus macaques but not in humans.

Clinical and experimental immunology·2013
Same journal

The Macrophage in Human Pathology: Update on its Role in Induction of the Immune Response. Proceedings of the 1998 European Macrophage Conference. September 17-19, 1998.

Research in immunology·1999
Same journal

Protective T-cell responses against tumours.

Research in immunology·1999
Same journal

Pathogenic and protective responses in parasitic infections.

Research in immunology·1999
Same journal

Pathogenic and protective T-cell responses in autoimmune diseases.

Research in immunology·1999
Same journal

Th1 and Th2 cells.

Research in immunology·1999
Same journal

Antigen receptors in lymphoid cell development and lymphocyte activation.

Research in immunology·1999
See all related articles

This study develops novel autologous cellular vaccines using patient

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Cancer immunotherapy aims to harness the patient's immune system to fight tumors.
  • Existing treatments have limitations, necessitating novel therapeutic strategies.
  • Autologous cellular vaccines offer a personalized approach to cancer treatment.

Purpose of the Study:

  • To develop and validate novel autologous cellular vaccines for cancer treatment.
  • To enhance anti-tumor immune responses through ex vivo processed antigen-presenting cells.
  • To assess the safety and efficacy of cellular vaccines in preclinical and clinical settings.

Main Methods:

  • Ex vivo processing of autologous mononuclear cells into monocyte-derived antigen-presenting cells (MD-APCs).
  • Maturation of MD-APCs with tumor-associated antigens or debris.

Related Experiment Videos

  • In vivo and in vitro evaluation of MD-APC functionality, immunogenicity, and anti-tumor activity in animal models and clinical trials.

    • Main Results:

    • Successful generation of functional ex vivo MD-APCs capable of antigen presentation.
    • Demonstrated immune response and anti-tumor effects in preclinical cancer models.
    • Initiation of clinical trials in melanoma and prostate cancer patients.

    Conclusions:

    • Autologous cellular vaccines represent a promising immunotechnology for cancer therapy.
    • Ex vivo processing and antigen loading of MD-APCs elicit potent anti-tumor immune responses.
    • Further clinical validation is expected to advance cellular and gene immunotherapy for various cancers.